Most-Favored-Nation Drug Pricing Order

In May 2025, President Trump issued an executive order aimed at lowering drug prices by tying U.S. costs to those in other developed countries. Known as the Most-Favored-Nation pricing rule, the order directs Medicare and other federal programs to pay no more than the lowest price charged in comparable OECD nations.

The policy also expands the reimportation of drugs from countries like Canada, giving patients additional pathways to access lower-cost prescriptions. The order represents one of the most aggressive attempts yet to tackle high pharmaceutical prices in the United States.

Proponents believe this approach will bring tangible savings for patients and taxpayers alike. By benchmarking against international prices, the government hopes to prevent pharmaceutical companies from overcharging American consumers.

Critics warn that the order may have unintended consequences, such as reduced investment in medical research or delayed availability of new drugs. Legal challenges are also expected, which could complicate or block implementation.

Despite uncertainties, the order reflects a clear policy shift toward using international comparisons to rein in U.S. drug costs. If successfully enforced, it could mark a turning point in the broader debate over affordable healthcare.